Khaznadar, F.; Petrovic, A.; Khaznadar, O.; Roguljic, H.; Bojanic, K.; Kuna Roguljic, L.; Siber, S.; Smolic, R.; Bilic-Curcic, I.; Wu, G.Y.;
et al. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy. J. Clin. Med. 2023, 12, 6561.
https://doi.org/10.3390/jcm12206561
AMA Style
Khaznadar F, Petrovic A, Khaznadar O, Roguljic H, Bojanic K, Kuna Roguljic L, Siber S, Smolic R, Bilic-Curcic I, Wu GY,
et al. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy. Journal of Clinical Medicine. 2023; 12(20):6561.
https://doi.org/10.3390/jcm12206561
Chicago/Turabian Style
Khaznadar, Farah, Ana Petrovic, Omar Khaznadar, Hrvoje Roguljic, Kristina Bojanic, Lucija Kuna Roguljic, Stjepan Siber, Robert Smolic, Ines Bilic-Curcic, George Y. Wu,
and et al. 2023. "Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy" Journal of Clinical Medicine 12, no. 20: 6561.
https://doi.org/10.3390/jcm12206561
APA Style
Khaznadar, F., Petrovic, A., Khaznadar, O., Roguljic, H., Bojanic, K., Kuna Roguljic, L., Siber, S., Smolic, R., Bilic-Curcic, I., Wu, G. Y., & Smolic, M.
(2023). Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy. Journal of Clinical Medicine, 12(20), 6561.
https://doi.org/10.3390/jcm12206561